Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer Risk for SBRT Early Lung Cancer Patients In Silico Study
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 20
Abstract
Objectives: This study performed dosimetry studies and secondary cancer risk assessments on using electronic portal imaging device (EPID) and cone beam computed tomography (CBCT) as image guided tools for the early lung cancer patients treated with SBRT. Methods: The imaging doses from MV-EPID and kV-CBCT of the Edge accelerator were retrospectively added to sixty-one SBRT treatment plans of early lung cancer patients. The MV-EPID imaging dose (6MV Photon beam) was calculated in Pinnacle TPS, and the kV-CBCT imaging dose was simulated and calculated by modeling of the kV energy beam in TPS using Pinnacle automatic modeling program. Three types of plans, namely PlanEPID, PlanCBCT and Planorigin, were generated with incorporating doses of EPID, CBCT and no imaging, respectively, for analysis. The effects of imaging doses on dose-volume-histogram (DVH) and plan quality were analyzed, and the excess absolute risk (EAR) of secondary cancer for ipsilateral lung was evaluated. Results: The regions that received less than 50 cGy were significantly impacted by the imaging doses, while the isodose lines greater than 1000 cGy were barely changed. The DVH values of ipsilateral lung increased the most in PlanEPID, followed by PlanCBCT. Compared to Planorigin on the average, the estimated EAR of ipsilateral lung in PlanEPID increased by 3.43%, while the corresponding EAR increase in PlanCBCT was much smaller (about 0.4%). Considering only the contribution of the imaging dose, the EAR values for the ipsilateral lung due to the MV-EPID dose in 5 years,10 years and 15 years were 1.49 cases, 2.09 cases and 2.88 cases per 104PY respectively, and those due to the kV-CBCT dose were about 9 times lower, correspondingly. Conclusions: The imaging doses produced by MV-EPID and kV-CBCT had little effects on the target dose coverage. The secondary cancer risk caused by MV-EPID dose is more than 8.5 times that of kV-CBCT.Keywords
Funding Information
- Nurture projects for basic research of Shanghai Chest Hospital (2019YNJCM05)
This publication has 28 references indexed in Scilit:
- Radiation exposure to patients from image guidance procedures and techniques to reduce the imaging doseRadiotherapy and Oncology, 2013
- Dosimetric properties and commissioning of cone-beam CT image beam line with a carbon targetStrahlentherapie und Onkologie, 2013
- Imaging Doses and Secondary Cancer Risk From Kilovoltage Cone-beam CT in Radiation TherapyHealth Physics, 2013
- Radiation dose and contralateral breast cancer risk associated with megavoltage cone-beam computed tomographic image verification in breast radiation therapyPractical Radiation Oncology, 2013
- Accuracy and inter-observer variability of 3D versus 4D cone-beam CT based image-guidance in SBRT for lung tumorsRadiation Oncology, 2012
- Kilovoltage Imaging Doses in the Radiotherapy of Pediatric Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay - A comparative studyRadiation Oncology, 2012
- Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non–Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Inclusion of the dose from kilovoltage cone beam CT in the radiation therapy treatment plansMedical Physics, 2009
- Extracranial Stereotactic Radioablation *Chest, 2003